solutions consulting research-development-advisory-group 
pharmaphorum
DECEMBER 14, 2022
Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. Pharma consultancy United BioSource, or UBC (not to be confused with pharma company UCB), has promoted former chief operating officer Bekki Brown to the role of president and CEO, effective January 1.
XTalks
JANUARY 17, 2024
Lupus, a complex autoimmune disease, has brought a substantial challenge to researchers and healthcare professionals. Understanding this condition and its various manifestations, as well as developing effective treatments, has been the focus of ongoing investigation in lupus clinical research for many years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 10, 2022
Instead of spending across a range of assets, commercial leads should double down on one to three therapies where they can test and deliver a digital solution that brings tangible value to the patient. Together, we understood many of the early pain points in the patient journey and focused our solution specifically on those pain points.
XTalks
JULY 19, 2022
Novavax’s vaccine was part of the US government’s Operation Warp Speed program to rapidly develop COVID-19 vaccines, through which it received $1.8 percent effective in preventing mild, moderate or severe COVID-19, with 17 cases of COVID-19 occurring in the vaccine group and 79 cases in the placebo group.
pharmaphorum
APRIL 15, 2021
When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. In the very early phase of development, Astellas also participates in public-private partnerships with academia, regulators, experts and beyond. The impact of COVID-19 and implications for the future.
The Pharma Data
JANUARY 25, 2021
“The establishment of an Advisory Board focusing on Alzheimer’s disease, and the recruitment of such an impressive group of scientific and clinical leaders in this field is an extremely important step forward for the Company,” stated Paul Brennan, NervGen’s President & CEO.
The Pharma Data
DECEMBER 17, 2020
Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.
Expert insights. Personalized for you.
96 
Let's personalize your content